Fig. 4From: Neurological and psychiatric safety of tafenoquine in Plasmodium vivax relapse prevention: a reviewNeuropsychiatric adverse events occurring before day 29 in P. vivax patients given tafenoquine/chloroquine versus primaquine/chloroquine [9,10,11]Back to article page